Inspira Pharmaceuticals Limited (Inspira or the Company), a biotechnology company developing novel bioactive molecules based on proprietary plant extracts to treat respiratory infections, today announced the appointment of Dr Jessica Jackson as an Non-Executive Director.
30 April 2021 – Inspira Pharmaceuticals Limited (Inspira or the Company), a biotechnology company developing novel bioactive molecules based on proprietary plant extracts to treat respiratory infections, today announced the appointment of Dr Jessica Jackson as an Non-Executive Director.
Dr Jessica (Jess) Jackson brings 12 years of experience in the bioscience sector, working in both industry and academic science in the UK and internationally. While working for the Regenerative Medicine Group at the University of South Australia, Jess performed some of the initial preclinical studies with Inspira’s core IPX technology, giving her the perfect background to support the ongoing progress of Inspira. A busy working mum of (soon to be) two, she currently works as a scientific writer for Meridian HealthComms Ltd, supporting several pharmaceutical clients with regulatory and grant applications, strategic communications, scientific event planning and manuscript writing. Jess is an accomplished scientist and has been assisting Inspira in the design of its R&D plan and scientific communications.
Rory McGoldrick, CEO of Inspira, commented: “Jess has a track record of supporting successful drug discovery and development. Inspira will benefit from Jess’ technical insight and experience at an exciting time in the development of our IPX technology. I am delighted to welcome Jess to the team at a time when we expect to accelerate activities and achieve numerous milestones over the next 12 months.”
Dr Jess Jackson said: “Inspira has a unique capability to develop inhaled treatments based on patented plant extracts that have shown strong anti-viral activity against SARS-CoV-2 in laboratory studies. I believe the Inspira formulations could offer important new treatment options for patients with respiratory infections, related to COVID-19 and other disorders. I look forward to expanding my contribution to the Company as Inspira advances its R&D activities towards clinical trials.”
ENDS
For more information, please contact:
Scius Communications Sue Charles - sue@sciuscommunications.com +44 (0)7968 726585
Katja Stout - katja@sciuscommunications.com +44 (0)7789 435990
ABOUT INSPIRA PHARMACEUTICALS
Inspira Pharmaceuticals Limited
Inspira Pharmaceuticals Limited is a UK-based company focused on the development and commercialisation of its proprietary IPX technology platform.
Inspira has identified novel plant-based IPX formulations that have potential therapeutic applications for the treatment of respiratory diseases, including COVID-19. The Company has demonstrated that its product candidates contain proteolytic enzymes that have shown to be effective in degrading biofilms relevant to lung infections and the spike protein on the SARS-CoV-2 virus. The spike protein is crucial for the virus to infect cells. Inspira’s products are being formulated for pulmonary delivery with the aim of inhibiting SARS-CoV-2 replication in the lungs as well as treating and preventing other respiratory infections.
